Owlet, Inc. (OWLT) Q3 2025 Earnings Call Transcript

Owlet, Inc. (OWLT) reported record Q3 2025 financial results, with revenue up 45% to $32 million, its first-ever quarterly operating profit of $1.2 million, and a sixth consecutive quarter of positive adjusted EBITDA at $1.6 million. This strong performance was driven by the successful launch of the Dream Sight camera, robust Dream Sock sales, and the company's unique market position as the sole FDA-cleared over-the-counter infant monitor following a recent FDA safety communication against unauthorized devices. Owlet also highlighted significant international growth, expansion of its Owlet360 subscription service to over 85,000 subscribers, and initial progress in healthcare channels through hospital partnerships. Consequently, the company raised its full-year 2025 revenue guidance to $103-$106 million and expects its first full year of adjusted EBITDA profitability, while strengthening its balance sheet with a recent $32 million equity offering.

Analysis

Owlet, Inc. (OWLT) reported an exceptional Q3 2025, achieving record revenue of $32 million, a 45% year-over-year increase, driven by the successful launch of its Dream Sight camera and robust core business momentum. This quarter marked a significant milestone with the company's first-ever operating profit of $1.2 million and its sixth consecutive quarter of positive adjusted EBITDA at $1.6 million. Gross profit also reached a record $16.2 million, yielding a 50.6% gross margin despite tariff impacts.

A critical market development is Owlet's unique position as the sole FDA-cleared over-the-counter infant monitoring device, following a recent FDA safety communication cautioning against unauthorized monitors. This regulatory clarity reinforces Owlet's market leadership, evidenced by a 40% share of total baby monitor dollars, and provides a substantial competitive advantage in the infant health technology sector.

Strategic growth initiatives are also gaining traction, with international revenue surging 171% year-over-year and the Owlet360 subscription service surpassing 85,000 paying subscribers with a 25% Dream Sock attach rate. The company is also making inroads into healthcare channels, exemplified by the CHKD partnership and Rhapsody integration for remote patient monitoring, which aims to accelerate hospital system adoption.

The company has raised its full-year 2025 revenue guidance to $103-$106 million, anticipating its first full year of adjusted EBITDA profitability. Furthermore, a recent $32 million equity offering has bolstered the balance sheet and simplified the capital structure, providing capital for continued investment in R&D, including future AI and telehealth capabilities, while maintaining financial discipline.

Key Decisions for Investors

• Monitor Owlet's continued revenue growth and sustained profitability, particularly given the raised 2025 guidance and first full year of adjusted EBITDA profitability.
• Assess the durability of the competitive moat created by the FDA clearance and its impact on market share gains against unauthorized devices.
• Evaluate the scalability and financial contribution of the Owlet360 subscription service and emerging healthcare partnerships, especially the Rhapsody integration for RPM.
• Consider the long-term potential of planned AI and telehealth integrations to enhance product stickiness and customer lifetime value, leveraging the strengthened balance sheet for R&D investments.